These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26324287)

  • 21. Global Delivery of Human Papillomavirus Vaccines.
    Wigle J; Fontenot HB; Zimet GD
    Pediatr Clin North Am; 2016 Feb; 63(1):81-95. PubMed ID: 26613690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adolescent human papillomavirus vaccination in the United States: Opportunities for integrating pharmacies into the immunization neighborhood.
    Fava JP; Colleran J; Bignasci F; Cha R; Kilgore PE
    Hum Vaccin Immunother; 2017 Aug; 13(8):1844-1855. PubMed ID: 28605256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus vaccination in HIV-infected women: need for increased coverage.
    Kojic EM; Rana AI; Cu-Uvin S
    Expert Rev Vaccines; 2016; 15(1):105-17. PubMed ID: 26599305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HPV vaccine].
    Yoshikawa H
    Nihon Rinsho; 2008 Oct; 66(10):1957-60. PubMed ID: 18939496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
    Watson M; Shaw D; Molchanoff L; McInnes C
    Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organization and quality of HPV vaccination programs in Europe.
    Elfström KM; Dillner J; Arnheim-Dahlström L
    Vaccine; 2015 Mar; 33(14):1673-81. PubMed ID: 25720792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V; Murtagh J
    Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and perception: What are the greatest enemies of HPV vaccination programmes?
    Bonanni P; Zanella B; Santomauro F; Lorini C; Bechini A; Boccalini S
    Vaccine; 2018 Aug; 36(36):5424-5429. PubMed ID: 28610824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and success of the human papillomavirus vaccine: time for a robust vaccination program in the United States and worldwide.
    Duska LR
    Clin Ther; 2014 Jan; 36(1):4-7. PubMed ID: 24417780
    [No Abstract]   [Full Text] [Related]  

  • 34. Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada.
    Drolet M; Deeks SL; Kliewer E; Musto G; Lambert P; Brisson M
    Vaccine; 2016 Apr; 34(16):1874-80. PubMed ID: 26954465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian school-based HPV vaccine programs and policy considerations.
    Shapiro GK; Guichon J; Kelaher M
    Vaccine; 2017 Oct; 35(42):5700-5707. PubMed ID: 28893472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.
    Šubelj M; Učakar V; Kraigher A; Klavs I
    Euro Surveill; 2016; 21(14):. PubMed ID: 27103551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events following immunization in Ontario's female school-based HPV program.
    Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
    Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine.
    Deceuninck G; Sauvageau C; Gilca V; Boulianne N; De Serres G
    Expert Rev Vaccines; 2018 Jan; 17(1):99-102. PubMed ID: 28972438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A new age range for HPV vaccination is preferred].
    MMW Fortschr Med; 2014 Sep; 156(15):13. PubMed ID: 25282919
    [No Abstract]   [Full Text] [Related]  

  • 40. HPV vaccination.
    Brotherton J
    Aust Fam Physician; 2007 Jun; 36(6):391; author reply 391. PubMed ID: 17582901
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.